New progress of study on hematopoietic stem cell transplantation for myelodysplastic syndromes.
- Author:
Bing WU
1
;
Yan WEI
;
Qian ZHANG
Author Information
1. Institute of Hematological Diseases, Lanzhou Military Area General Hospital, Lanzhou, Gansu Province, China.
- Publication Type:Journal Article
- MeSH:
Hematopoietic Stem Cell Transplantation;
methods;
Humans;
Myelodysplastic Syndromes;
surgery;
Transplantation Conditioning;
methods;
Treatment Outcome
- From:
Journal of Experimental Hematology
2012;20(2):510-513
- CountryChina
- Language:Chinese
-
Abstract:
Hematopoietic stem cell transplantation (HSCT) is the only way to cure myelodysplastic syndromes. At present there are several myelodysplastic syndromes scoring systems, including the International Prognostic Scoring System (IPSS), WHO Prognostic Scoring System (WPSS) and Simplified MDS Risk Score. These score systems can not only predict the probability of transplant success, but also help to determine the time of transplantation. For the older patient with serious complication, a suitable conditioning regimen can lower the risk of treatment-related mortality. Complication management, individualized conditioning regimen, optimal timing of transplantation and donor selection should improve the curative effect of HSCT. However, post-transplantation relapse and graft-versus-host disease (GVHD) remain to be solved and further investigations are needed. In this review the MDS scoring system, factors influencing HSCT efficacy, the selection of HSCT donors and timing, the preconditioning intensity before HSCT and evaluation of HSCT efficacy are summarized.
